Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome.
Various studies suggest alpha 2-adrenergic receptor (alpha 2AR) dysregulation in panic disorder (PD). Platelet alpha 2-AR exist in high- and low-conformational states as a function of their coupling to Gi protein. alpha 2AR coupling is important in signal transduction and is modulated by antidepressants. alpha 2AR density in the high- and low-conformational states, agonist affinity, and coupling efficiency were investigated in 21 healthy controls, 21 drug-free PD patients, and eight imipramine-treated patients using norepinephrine displacement of 3H-yohimbine binding. Percentage of receptors in the high-conformational state (%RH) and the ratio of the agonist dissociation constant to the receptor in the low-/high-conformational state (KL/KH), calculated from displacement experiments, were used as coupling indices. Patients had high alpha 2AR density in both conformational states. %RH and KL/KH ratio were significantly different, particularly in patients with Hamilton scale for depression (HAMD) scores > or = 15. Imipramine treatment (29 weeks) had no effect on alpha 2AR density or coupling, despite improvement in anxiety ratings. High pretreatment alpha 2AR density and coupling predicted low severity of anxiety after treatment. Increased alpha 2AR density and abnormal coupling may represent an adaptive mechanism or trait marker in PD.
Gurguis
G N
GN
Department of Veterans Affairs Medical Center, Dallas, Texas 75216, USA.
Antai-Otong
D
D
Vo
S P
SP
Blakeley
J E
JE
Orsulak
P J
PJ
Petty
F
F
Rush
A J
AJ
D000328:Adult; D000379:Agoraphobia / Q000097:blood / Q000188:drug therapy / Q000523:psychology; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D015536:Down-Regulation / Q000187:drug effects; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000097:blood*; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D016584:Panic Disorder / Q000097:blood* / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales; D011869:Radioligand Assay; D018341:Receptors, Adrenergic, alpha-2 / Q000097:blood*; D016896:Treatment Outcome
D000929:Antidepressive Agents, Tricyclic; D018341:Receptors, Adrenergic, alpha-2; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D007099:Imipramine